A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma

Study Purpose

The aim of study is to investigate the efficacy, safety, immunogenicity, pharmacokinetics, and pharmacodynamics of BCD-217 followed by prolgolimab monotherapy versus prolgolimab monotherapy as first-line therapy in subjects with unresectable or metastatic melanoma.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

1. Signed informed consent and the subject's ability to comply with the requirements of the clinical study protocol; 2. Age ≥18 years at the time of signing the informed consent form; 3. Histologically confirmed melanoma (with available documented evidence of relevant investigations); 4. Untreated unresectable stage III melanoma or untreated metastatic (stage IV) melanoma; 5. Available blocks for histological examination and/or the subject's consent to undergo biopsy ; 6. Consent to the evaluation of the PD-L1 status and BRAF V600 mutation status at a central laboratory; 7. ECOG score 0-1; 8. Life expectancy of at least 12 weeks ; 9. Measurable target tumor lesions (at least 1 lesion) according to RECIST 1.1 criteria , confirmed by central independent reviewer; 10. In subjects of childbearing potential, willingness to use reliable contraceptive measures throughout the study, from the signing of the informed consent form and for additional 24 weeks after the administration of the last dose of the investigational product.

Exclusion Criteria:

1. Indications for radical (surgical, radiation) therapy; 2. A history of previous systemic antitumor therapy for unresectable or metastatic melanoma ; 3. Prior therapy with checkpoint inhibitors (e.g., anti-CTLA-4 and/or anti-PD-1/PD-L1/PD-L2 products); 4. Prior therapy with BRAF and MEK protein kinase inhibitors; 5. Use of immunostimulants, monoclonal antibodies and/or colony-stimulating factors within less than 4 weeks prior to randomization in the study; 6. Ocular melanoma; 7. Mucosal melanoma; 8. CNS metastases; 9. Impossibility to determine PD-L1 status and/or BRAF status; 10. Subjects with severe comorbidities, life-threatening acute complications of the primary disease (including massive pleural, pericardial, or peritoneal effusions requiring intervention , pulmonary lymphangitis, bleeding, or organ perforation) at the time of signing the informed consent form; 11. Ongoing concomitant diseases at the time of screening, which increase the risk of severe adverse events during the administration of the study therapy:
  • - stable angina, functional class III-IV; - unstable angina or a history of myocardial infarction within less than 6 months prior to signing the informed consent form; - moderate to severe heart failure (classes III and IV according to NYHA classification); - uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg) ; - a history of atopic asthma , angioedema; - respiratory failure (moderate to severe), grade 3 or 4 chronic obstructive pulmonary disease; - any other concomitant diseases (including, but not limited to, metabolic, hematological, renal, hepatic, pulmonary, neurological, endocrine, cardiac, infectious, gastrointestinal disorders), which expose the subject to an unacceptable risk during the study therapy; 12.
Known or suspected systemic autoimmune diseases (including, but not limited to, systemic lupus erythematosus, Crohn's disease, nonspecific ulcerative colitis, systemic scleroderma, inflammatory myopathy, mixed connective tissue disease, overlap syndrome, etc.) ; 13. History of interstitial pulmonary disease or pneumonitis requiring systemic glucocorticoids; 14. The need for glucocorticoid therapy (at >10 mg/day prednisolone equivalent doses) or any other drugs with immunosuppressive effects within 14 days prior to randomization; 15. Hematologic abnormalities :
  • - neutrophils <1.5×109/L; - platelets <100×109/L; - hemoglobin <90 g/L; 16.
Renal impairment: creatinine ≥2.5×ULN; 17. Hepatic impairment :
  • - total bilirubin ≥3×ULN (except for subjects with Gilbert's syndrome, in whom bilirubin levels should not exceed 50 μmol/L), - AP, AST or ALT ≥2.5×ULN (≥5×ULN in case of subjects with liver metastases); 18.
Any antitumor treatment within less than 4 weeks or surgery within less than 28 days prior to randomization within the study; 19. History of oncological disease, except for radically treated diseases with remission for over 5 years prior randomization in this study ; 20. Conditions limiting the subject's ability to comply with the Protocol requirements (in the Investigator's opinion ); 21. Participation in other clinical studies within less than 30 days prior to randomization and during this clinical study ; 22. Acute infections or activation of chronic infectious diseases or systemic antibacterial therapy within less than 28 days prior to randomization; 23. Active hepatitis B, active hepatitis C (confirmed by PCR), active syphilis, HIV-infection, currently or previously ; 24. Impossibility to administer the investigational product intravenously; 25. Impossibility to administer intravenous contrast agents (including due to hypersensitivity to contrast media); 26. Hypersensitivity to any of the components of BCD-100 or BCD-217; 27. A history of hypersensitivity to monoclonal antibody products; 28. Pregnancy or breastfeeding.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05732805
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 3
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Biocad
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

N/A
Principal Investigator Affiliation N/A
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries Belarus, India, Russian Federation
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Melanoma, Melanoma (Skin), Melanoma Stage III, Melanoma Stage IV, Melanoma Unresectable, Melanoma Metastatic, Melanoma Advanced
Additional Details

This study is designed as a phase III, randomized, double-blind, placebo-controlled study. After the stratification procedure, subjects are randomized in a 1:1 ratio into 2 groups: - BCD-217 + placebo (4 doses) → prolgolimab (BCD-217 group) - Prolgolimab + placebo (4 doses) → prolgolimab (BCD-100 monotherapy group)

Arms & Interventions

Arms

Experimental: BCD-217 (nurulimab + prolgolimab)

BCD-217 followed by prolgolimab 1 mg/kg monotherapy.

Active Comparator: BCD-100 (prolgolimab)

Prolgolimab monotherapy.

Interventions

Biological: - BCD-217

Subject recieves BCD-217 0.2 mL/kg, which is equivalent to 1 mg/kg nurulimab + 3 mg/kg prolgolimab, as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

Biological: - BCD-100

Subject recieves prolgolimab 3 mg/kg as an intravenous infusion once every 3 weeks (Q3W) simultaneously with placebo, a total of 4 intravenous infusions. Beginning with the 5th infusion, subjects are switched to prolgolimab 1 mg/kg monotherapy once every 2 weeks (Q2W).

Biological: - Placebo

Placebo

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Babruysk, Belarus

Status

Recruiting

Address

Healthcare Institution "Bobruisk Interdistrict Oncological Dispensary"

Babruysk, ,

Site Contact

Igor A Sharf

uz@bmod.by

+375225 736262

Brest, Belarus

Status

Recruiting

Address

Healthcare Institution "Brest Regional Oncological Dispensary"

Brest, ,

Site Contact

Vitalii S Volkov

biocad@biocad.ru

+375 (0162) 97-83-03

Gomel, Belarus

Status

Recruiting

Address

Health Institution "Gomel Regional Clinical Oncology Center"

Gomel, ,

Site Contact

Vasilii N Belyakovskii

mail@gokod.by

+7 (812) 380 49 33

Grodno, Belarus

Status

Recruiting

Address

Health care institution "Grodno University Clinic"

Grodno, ,

Site Contact

Dmitrii P Norik

regclinic@gocb.by

+375 (152) 436230

Lesnoy, Belarus

Status

Recruiting

Address

State Institution "Republican Scientific and Practical Center of Oncology and Medical Radiology named after A.I. N.N. Alexandrov"

Lesnoy, ,

Site Contact

Nikolaii B Ermakov

oncobel@omr.med.by

(+375 17) 265-23-01

Minsk, Belarus

Status

Recruiting

Address

Healthcare Institution "Minsk City Clinical Cancer Center"

Minsk, , 220013

Site Contact

Svetlana A Demidova

onko@mgkod.by

+375 17 237 32 90

Mogilev, Belarus

Status

Recruiting

Address

State Institution "Mogilev Regional Oncological Dispensary"

Mogilev, ,

Site Contact

Natalia I Ivanova

info@mood.by

+7 (812) 380 49 33

Vitebsk, Belarus

Status

Recruiting

Address

Healthcare Institution "Vitebsk Regional Clinical Oncology Center"

Vitebsk, ,

Site Contact

Aleksei L Obukhov

biocad@biocad.ru

+ 375 (212) 57-40-31

Fortis Hospital, Faridabad, India

Status

Recruiting

Address

Fortis Hospital

Faridabad, ,

Site Contact

Amit Bhargava, MD

biocad@biocad.ru

+7 (812) 380 49 33

Kasturba Medical College and Hospital, Mangalore, India

Status

Recruiting

Address

Kasturba Medical College and Hospital

Mangalore, ,

Site Contact

M S Athiyamaan, MD

biocad@biocad.ru

+7 (812) 380 49 33

TATA Memorial Hospital, Mumbai, India

Status

Recruiting

Address

TATA Memorial Hospital

Mumbai, ,

Site Contact

Prabhat G Bhargava, MD

biocad@biocad.ru

+7 (812) 380 49 33

Nagpur, India

Status

Recruiting

Address

HealthCare Global Enterprises Ltd, NCHRI Cancer Center

Nagpur, ,

Site Contact

Ajay O Mehta, MD

biocad@biocad.ru

+7 (812) 380 49 33

Nashik, India

Status

Recruiting

Address

HealthCare Global Enterprises Ltd Manavata cancer Centre

Nashik, ,

Site Contact

Rajnish Nagarkar, MD

biocad@biocad.ru

+7 (812) 380 49 33

Sankalp Superspeciality Hospital, Nashik, India

Status

Recruiting

Address

Sankalp Superspeciality Hospital

Nashik, ,

Site Contact

Bhushan Nemade, MD

biocad@biocad.ru

+7 (812) 380 49 33

All India Institute of Medical Science, New Delhi, India

Status

Recruiting

Address

All India Institute of Medical Science

New Delhi, ,

Site Contact

Sameer Rastogi, MD

biocad@biocad.ru

+7 (812) 380 49 33

Pune, India

Status

Recruiting

Address

Deenanath Mangeshkar Hospital & Research Center

Pune, ,

Site Contact

Chetanavata Deshmukh, MD

biocad@biocad.ru

+7 (812) 380 49 33

Pune, India

Status

Recruiting

Address

PDEAS Ayurved Rugnalaya & Steriling Multispeciality Hospital

Pune, ,

Site Contact

Rakesh Neve, MD

biocad@biocad.ru

+7 (812) 380 49 33

Horizon Mulitispeciality Hospital, Sangli, India

Status

Recruiting

Address

Horizon Mulitispeciality Hospital

Sangli, ,

Site Contact

Vaibhav Amale, MD

biocad@biocad.ru

+7 (812) 380 49 33

Shalby Hospital, Surat, India

Status

Recruiting

Address

Shalby Hospital

Surat, ,

Site Contact

Kaushal Patel, MD

biocad@biocad.ru

+7 (812) 380 49 33

Kiran Multispeciality hospital &Research, Sūrat, India

Status

Recruiting

Address

Kiran Multispeciality hospital &Research

Sūrat, ,

Site Contact

Anshul Agrawal, MD

biocad@biocad.ru

+7 (812) 380 49 33

Chelyabinsk, Chelyabinsk Oblast, Russian Federation

Status

Recruiting

Address

Chelyabinsk Regional Clinical Center for Oncology and Nuclear Medicine

Chelyabinsk, Chelyabinsk Oblast, 454087

Site Contact

Natalya V Fadeeva, MD, PhD

biocad@biocad.ru

+7-(812)-380-49-34

LLC "New Clinic", Pyatigorsk, Stavropol Krai, Russian Federation

Status

Recruiting

Address

LLC "New Clinic"

Pyatigorsk, Stavropol Krai, 357500

Site Contact

Victoria V Chistyakova

newclinic@list.ru

+7 (8793) 97 45 31

Arkhangelsk Clinical Oncology Dispensary, Arkhangel'sk, Russian Federation

Status

Recruiting

Address

Arkhangelsk Clinical Oncology Dispensary

Arkhangel'sk, ,

Site Contact

Yana S Chapko, MD

secretar@onko29.ru

+7 (8182) 27 57 74

Barnaul, Russian Federation

Status

Recruiting

Address

Regional State Budgetary Institution of Health Care "Altai Regional Oncological Dispensary"

Barnaul, ,

Site Contact

Sergei A Kolomiets

akod@zdravalt.ru

+7 (385) 250 73 55

Limited Liability Company "EVIMED", Chelyabinsk, Russian Federation

Status

Recruiting

Address

Limited Liability Company "EVIMED"

Chelyabinsk, ,

Site Contact

Oleg A Gladkov

info@evimeds.ru

+7 (351) 220 12 22

Chelyabinsk, Russian Federation

Status

Recruiting

Address

Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Chelyabinsk"

Chelyabinsk, ,

Site Contact

Olga V Kurchenkova

dkbsecr@dkb74.ru

+7 (351) 211 12 03

Gatchina, Russian Federation

Status

Recruiting

Address

State budgetary healthcare institution Leningrad Regional Clinical Hospital

Gatchina, ,

Site Contact

Mariia V Smagina

lokb@47lokb.ru

+7 (812) 670 18 88

Kazan, Russian Federation

Status

Recruiting

Address

State Autonomous Health Institution "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"

Kazan, ,

Site Contact

Sufia Z Safina, MD

rkod.mzrt@tatar.ru

+7 (843) 202 3 202

Kemerovo, Russian Federation

Status

Recruiting

Address

State budgetary health care institution "Kuzbass clinical oncological dispensary named after M.S. Rappoport"

Kemerovo, ,

Site Contact

Artur Z Azanov

05-guz-okod@kuzdrav.ru

+7 (3842) 54 14 98

Kostroma, Russian Federation

Status

Recruiting

Address

Regional Goverment Budgetary Healthcare State "Kostroma Oncology Center"

Kostroma, , 156005

Site Contact

Vera A Vaschenko

biocad@biocad.ru

7 (4942) 37 37 37

Kuz'molovskiy, Russian Federation

Status

Recruiting

Address

State Budgetary Institution of Healthcare "Leningrad Regional Clinical Oncological Dispensary named after V.I. L.D. Romana"

Kuz'molovskiy, ,

Site Contact

Igor O Belogortsev

onco@lokod.ru

+7 (813) 697 39 52

Moscow, Russian Federation

Status

Recruiting

Address

"Russian Cancer Research Center named after N.N. Blokhin "of the Ministry of Health of the Russian Federation

Moscow, ,

Site Contact

Leo Demidov

siljutina@biocad.ru

+74993241504

Moscow, Russian Federation

Status

Recruiting

Address

Branch of Hadassah Medical LTD Limited Liability Company

Moscow, ,

Site Contact

Igor A Utiashev

info@hadassah.moscow

+7 (495) 186 41 48

Moscow, Russian Federation

Status

Recruiting

Address

Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Moscow, ,

Site Contact

Elena V Poddubskaya

rektorat@sechenov.ru

+7 (499) 248 05 53

Joint Stock Company "K31 City", Moscow, Russian Federation

Status

Recruiting

Address

Joint Stock Company "K31 City"

Moscow, ,

Site Contact

Elena F Satirova

media@k31.ru

+7 (495) 324 10 92

JSC "Medsi Group", Moscow, Russian Federation

Status

Recruiting

Address

JSC "Medsi Group"

Moscow, ,

Site Contact

Anastasiia S Mochalova

biocad@biocad.ru

+7 (495) 021 47 02

Moscow City Oncology Hospital No. 62, Moscow, Russian Federation

Status

Recruiting

Address

Moscow City Oncology Hospital No. 62

Moscow, ,

Site Contact

Daniil L Stroyakovsky, MD, PhD

gob62@zdrav.mos.ru

+7 (495) 536 01 00

Moscow, Russian Federation

Status

Recruiting

Address

State budgetary health care institution of the city of Moscow "City Clinical Oncology Hospital No. 1 of the Department of Health of the City of Moscow"

Moscow, ,

Site Contact

Marina A Lyadova

gkob1@zdrav.mos.ru

+7 (499) 261 30 42

Moscow, Russian Federation

Status

Recruiting

Address

State Budgetary Institution of Healthcare of the City of Moscow "Moscow Multidisciplinary Clinical Center "Kommunarka" of the Department of Health of the City of Moscow"

Moscow, ,

Site Contact

Mikhail Yu Fedyanin

mmcc@zdrav.mos.ru

+7 (495) 744 07 03

Nizhny Novgorod, Russian Federation

Status

Recruiting

Address

Nizhny Novgorod Region State Budgetary Healthcare Facility "Clinical Diagnostics Center"

Nizhny Novgorod, , 603006

Site Contact

Irina S Shumskaya

sekretar@nnood.ru

+7 (831) 282 00 01

LLC "DobroMed", Novosibirsk, Russian Federation

Status

Recruiting

Address

LLC "DobroMed"

Novosibirsk, ,

Site Contact

Artem A Zeidlits

biocad@biocad.ru

+7 (383) 209 21 00

Novosibirsk, Russian Federation

Status

Recruiting

Address

State Budgetary Healthcare Institution "Novosibirsk Regional Clinical Oncology Center" of the Novosibirsk Region

Novosibirsk, ,

Site Contact

Vadim V Kozlov

nood@nso.ru

+7 (383) 382 80 46

Obninsk, Russian Federation

Status

Recruiting

Address

Federal State Budgetary Institution "National Medical Research Center for Radiology" of the Ministry of Health of the Russian Federation

Obninsk, ,

Site Contact

Natalia A Falaleeva

mrrc@mrrc.obninsk.ru

+7 (495) 150 11 22

Omsk, Russian Federation

Status

Recruiting

Address

Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Center"

Omsk, ,

Site Contact

Anastasiya V Zimina

biocad@biocad.ru

+7 (3812) 60 16 95

Pesochnyy, Russian Federation

Status

Recruiting

Address

Federal State Budgetary Institution "National Medical Research Center of Oncology named after N.N. Petrov" of the Ministry of Health of the Russian Federation (FSBI "N.N. Petrov National Medical Research Center of Oncology" of the Ministry of Health of Ru

Pesochnyy, ,

Site Contact

Svetlana A Protsenko

oncl@rion.spb.ru

+7 (812) 43 99 555

LLC "Clinical Trials", Saint Petersburg, Russian Federation

Status

Recruiting

Address

LLC "Clinical Trials"

Saint Petersburg, , 188663

Site Contact

Igor O Belogortsev

biocad@biocad.ru

+7 (911) 218 59 27

JSC "Modern Medical Technologies", Saint Petersburg, Russian Federation

Status

Recruiting

Address

JSC "Modern Medical Technologies"

Saint Petersburg, , 190013

Site Contact

Svetlana V Odintsova, MD

biocad@biocad.ru

+7-(812)-380-49-34

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Federal State Budgetary Educational Institution of Higher Education "Saint Petersburg State University"

Saint Petersburg, ,

Site Contact

Julia V Semiletova

spbu@spbu.ru

+7 (812) 328 20 00

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Federal State Budgetary Health Institution St. Petersburg Clinical Hospital of the Russian Academy of Sciences

Saint Petersburg, ,

Site Contact

Ivan V Rikov

hospital@spbkbran.ru

+7 (812) 222 22 72

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Limited Liability Company "EuroCityClinic"

Saint Petersburg, ,

Site Contact

Sergei V Orlov

info@eurocityclinic.ru

+7 (812) 618 08 00

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Limited Liability Company "Oncological Research Center"

Saint Petersburg, ,

Site Contact

Timur T Agishev

reception@spbonc.ru

+7 (812) 409 96 63

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Limited Liability Company "Stepmed Clinic"

Saint Petersburg, ,

Site Contact

Andrei V Kutkovich

clinic@step-med.com

+7 (812) 219 50 27

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Limited Liability Company "Strategic Medical Systems"

Saint Petersburg, ,

Site Contact

Ivan S Sardaryan

info@mt.clinic

+7 (921) 300 86 18

LLC "AV medical group", Saint Petersburg, Russian Federation

Status

Recruiting

Address

LLC "AV medical group"

Saint Petersburg, ,

Site Contact

Timur T Andabekov, PhD in Medicine

biocad@biocad.ru

+7 (921) 907 71 57

Saint Petersburg, Russian Federation

Status

Recruiting

Address

N.N. Petrov National Medicine Research Center of oncology

Saint Petersburg, ,

Site Contact

Artem N Poltoratski

oncl@rion.spb.ru

+7 (812) 439 95 55

Saint Petersburg, Russian Federation

Status

Recruiting

Address

Private Medical Institution Evromedservis

Saint Petersburg, ,

Site Contact

Konstantin D Pen'kov

emeds.spb@yandex.ru

+7 (812) 644 10 27

Samara, Russian Federation

Status

Recruiting

Address

Private institution educational organization of higher education "Medical University "Reaviz"

Samara, ,

Site Contact

Mikhail V Kopp

mail@reaviz.ru

+7 (800) 600 24 00

Sankt Petersburg, Russian Federation

Status

Recruiting

Address

State budgetary health care institution "St. Petersburg Clinical Scientific and Practical Center of Specialized Medical Assistance (Oncological)"

Sankt Petersburg, ,

Site Contact

Vladimir Moiseenko, MD

siljutina@biocad.ru

+78125739191

Saransk, Russian Federation

Status

Recruiting

Address

Federal State Educational Institution of Higher Professional Education "Mordovia State University N.P. Ogareva "

Saransk, ,

Site Contact

Pavel Skopin, PhD

siljutina@biocad.ru

+7 (812) 380 49 33

Oncology Dispensary 2, Sochi, Russian Federation

Status

Recruiting

Address

Oncology Dispensary 2

Sochi, , 354057

Site Contact

DmitriI V Kirtbaya

onko13@sochi.com

+7 (862) 261 43 93

City Hospital #40, Kurortny district, St. Petersburg, Russian Federation

Status

Recruiting

Address

City Hospital #40, Kurortny district

St. Petersburg, ,

Site Contact

Dmitrii V Gladishev

b40@zdrav.spb.ru

+7 (812) 437 46 18

Volgograd, Russian Federation

Status

Recruiting

Address

State Health Care Institution "Volgograd Regional Clinical Oncology Dispensary № 1"

Volgograd, ,

Site Contact

Nadezhda V Kovalenko, MD

vokod@volganet.ru

+7 (8442) 609 608

Yaroslavl, Russian Federation

Status

Recruiting

Address

State Regional Budgetary Healthcare Institution "Regional Clinical Oncology Hospital" of the Yaroslavl Region

Yaroslavl, , 150054

Site Contact

Nikolay V Kislov

yar_okob@mail.ru

+7(4852) 208 100

Stay Informed & Connected